Beijing Tongren Hospital Capital Medical University
Clinical trial of acellular porcine corneal matrix in the treatment of corneal ulcer
Zhiqiang Pan1, Liuhe Zou1, Mingchang Zhang4, Yueqin Zhang3, Yingping Deng2.
1Ophthalmology, Beijing Tongren Hospital Capital Medical University, Beijing, People's Republic of China; 2Ophthalmology, West China Hospital Sichuan University, Chengdu, People's Republic of China; 3Ophthalmology, Department of Ophthalmology, center of Henan Province, Zhengzhou, People's Republic of China; 4Ophthalmology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, People's Republic of China
Background: Recently, the serious shortage of donated corneas limited the corneal transplantation. Porcine corneas might prove acceptable substitutes, but there are still many hurdles to be overcome, such as antigenic differences between species. We urgently need for a cornea substitutewhich is biocompatible and no obvious rejection and toxicity, to replace the human cornea donors. In the present study, we observe the efficacy and safety of a cellular porcine corneal matrix in the treatment of corneal ulcer.
Methods: A total of 115 patients who were diagnosed as corneal ulcer were observed. Dissect the recipient cornea by designing the extent (1 mm bigger than ulcer diameter) and depth of the dissection in order to remove all affected corneal tissue whilst preserving as much healthy tissue as possible. Suture rehydrated acellular porcine corneal matrix on the ulcer as the same as conventional lamellar keratoplasty. The outcome of treatment was assessed at 6 months. Observation index are eye irritation, corneal transparent, corneal edema, corneal stromal dissolution, epithelial healing, corneal loss, corneal neovascularization.
Results: We had observed the whole 115 patient at 6 months, most of the patients (85.32%) felt no eye irritation, 11.93% corneas were completely transparent, 62.39% corneas were slight opacity, 94.5% corneal epitheliums completely healed, 92.66% had no corneal edema, 88.07% had no corneal dissolution, 100% had no corneal loss, 66.97% had no corneal neovascularization, 1 adverse event had nothing to do with the research instrument but led to graft loss. On the basis of the formula, at 6 month after surgery the total efficiency is 94.5%. Conclusions: Acellular porcine corneal matrix can promote the regeneration of corneal epithelium and the synthesis of corneal matrix for the affected area, and have good tissue compatibility. It is safe in the treatment of corneal ulcer.
07:00 - 08:00
|Cell & Tissue Xenotransplantation: Tolerance||Clinical trial of acellular porcine corneal matrix in the treatment of corneal ulcer||Room 109|